Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Gilead Sciences
Gilead Sciences
3 Takeover Candidates in the Drug Space
TheStreet.com
Mon, 01/9/17 - 09:45 am
M&A
Gilead Sciences
JNJ
Pfizer
Merck
Novartis
Eli Lilly
Bristol-Myers Squibb
Biogen
Biotech Investing: 3 Bold Predictions for 2017
Motley Fool
Fri, 01/6/17 - 09:47 am
biotech
Incyte
Biogen
Biomarin
Gilead Sciences
Illumina
Valeant Is A Strong Acquisition Target
Seeking Alpha
Thu, 01/5/17 - 09:36 am
Valeant Pharmaceuticals
M&A
Gilead Sciences
Pfizer
Amgen
Biotech Stocks: What to Watch in 2017
Motley Fool
Tue, 01/3/17 - 10:02 am
biotech
M&A
drug launches
Gilead Sciences
Incyte
Spinraza
Biogen
Ionis Pharmaceuticals
Amgen
Regeneron
Sanofi
This Army Vet Is Fighting Hep C With Big Pharma’s Help
Bloomberg
Thu, 12/29/16 - 10:18 am
hepatitis C
AbbVie
Merck
Gilead Sciences
The Most Likely Incyte Acquisition Deal for 2017?
Motley Fool
Sat, 12/24/16 - 12:11 pm
M&A
Incyte
Gilead Sciences
Lilly
Novartis
Agenus
Valeant Is The Answer To Gilead's Problems
Seeking Alpha
Fri, 12/23/16 - 09:53 am
Valeant Pharmaceuticals
Gilead Sciences
Will 2017 Be Gilead Sciences Inc.'s Worst Year Yet?
Motley Fool
Thu, 12/22/16 - 10:15 am
Gilead Sciences
Could Gilead Sciences' Game-Changing HIV Pill Solve Its Growth Problem?
Motley Fool
Tue, 12/20/16 - 12:11 pm
Gilead Sciences
HIV
Truvada
The Most Expensive Drugs of 2016
Motley Fool
Mon, 12/19/16 - 11:32 am
drug pricing
Gilead Sciences
Harvoni
Sovaldi
H.P. Acthar
Mallinckrodt
Shire
Cinryze
Daklinza
Bristol-Myers Squibb
Gilead’s Patent Loss to Merck Started With a Broken Friendship
Bloomberg
Mon, 12/19/16 - 10:55 am
Gilead Sciences
Merck
patents
hepatitis C
Sovaldi
Harvoni
Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?
Motley Fool
Sat, 12/17/16 - 12:23 pm
biotech
Allergan
Gilead Sciences
Genfit
Intercept Pharmaceuticals
NASH
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Bloomberg
Fri, 12/16/16 - 09:51 am
Merck
patents
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Gilead Sciences Inc.'s Best Moves in 2016
Motley Fool
Thu, 12/15/16 - 12:00 pm
Gilead Sciences
NASH
hepatitis C
filgotinib
Galapagos
The 3 Most Profit-Friendly Biotech Stocks
Motley Fool
Tue, 12/13/16 - 10:23 am
biotech
biotech stocks
United Therapeutics
Gilead Sciences
Biogen
Gilead's HCV NDA Means Nothing
Seeking Alpha
Sun, 12/11/16 - 11:55 am
Gilead Sciences
hepatitis C
SOF/VEL/VOX
Epclusa
AbbVie
Gilead offers rare apology to payers over the hep C drug sticker shock
Endpoints
Thu, 12/8/16 - 10:06 am
Gilead Sciences
drug pricing
Pharma CEOs
Sovaldi
John Milligan
Gilead Sciences Inc.'s Worst Moves in 2016
Motley Fool
Tue, 12/6/16 - 10:44 pm
Gilead Sciences
dividends
hepatitis C
M&A
Switching course, Gilead markets HIV drug for prevention
Yahoo/Reuters
Thu, 12/1/16 - 10:28 am
Truvada
Gilead Sciences
HIV
5 Things Gilead Sciences' CEO Just Said That You Need to Know
Motley Fool
Wed, 11/30/16 - 09:49 pm
Gilead Sciences
John Milligan
Pharma CEOs
Pages
« first
‹ previous
…
42
43
44
45
46
47
48
49
50
…
next ›
last »